Reconstitution and handling Tirzepatide is supplied as a lyophilised vial and should be handled using standard peptide reconstitution procedures appropriate to the research setting
Important caveat: injectable and IV NAD+ are not FDA-approved (nor approved by any major regulator) for energy, metabolic or longevity uses, and their safety and efficacy for these marketed uses are not established
Insert a sterile syringe into the bacteriostatic water vial and withdraw the amount needed based on the dosing protocol
NICE has issued technology appraisals for semaglutide 2.4 mg (Wegovy) for weight management (TA875) and for tirzepatide (Mounjaro) for managing overweight and obesity , each with defined eligibility criteria
This is true despite the wide range of steady state values [Table 1 and Figure 2A]
Benefits of Topical Administration Direct Skin Benefits: Targets signs of aging including wrinkles, fine lines, and loss of elasticity